{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Winzeler B"],"funding":["Swiss National Science Foundation","Swiss Academy of Medical Sciences","G.& J. Bangerter-Rhyner Foundation",", University Hospital and University of Basel"],"pagination":["e151800"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8516458"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["131(20)"],"pubmed_abstract":["BackgroundPrimary polydipsia, characterized by excessive fluid intake, carries the risk of water intoxication and hyponatremia, but treatment options are scarce. Glucagon-like peptide 1 (GLP-1) reduces appetite and food intake. In experimental models, GLP-1 has also been shown to play a role in thirst and drinking behavior. The aim of this trial was to investigate whether GLP-1 receptor agonists reduce fluid intake in patients with primary polydipsia.MethodsIn this randomized, double-blind, placebo-controlled, 3-week crossover trial, 34 patients with primary polydipsia received weekly dulaglutide (1.5 mg, Trulicity) in one treatment segment and placebo (0.9% sodium chloride) in the other. During the last treatment week, patients attended an 8-hour evaluation visit with free access to water"],"journal":["The Journal of clinical investigation"],"pubmed_title":["A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia."],"pmcid":["PMC8516458"],"funding_grant_id":["162608","-"],"pubmed_authors":["Sailer CO","Christ-Crain M","Coynel D","Refardt J","Vogt DR","Urwyler SA","Zanchi D","Winzeler B"],"additional_accession":[]},"is_claimable":false,"name":"A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia.","description":"BackgroundPrimary polydipsia, characterized by excessive fluid intake, carries the risk of water intoxication and hyponatremia, but treatment options are scarce. Glucagon-like peptide 1 (GLP-1) reduces appetite and food intake. In experimental models, GLP-1 has also been shown to play a role in thirst and drinking behavior. The aim of this trial was to investigate whether GLP-1 receptor agonists reduce fluid intake in patients with primary polydipsia.MethodsIn this randomized, double-blind, placebo-controlled, 3-week crossover trial, 34 patients with primary polydipsia received weekly dulaglutide (1.5 mg, Trulicity) in one treatment segment and placebo (0.9% sodium chloride) in the other. During the last treatment week, patients attended an 8-hour evaluation visit with free access to water","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2026-05-08T22:37:43.104Z","creation":"2022-02-11T16:20:03.204Z"},"accession":"S-EPMC8516458","cross_references":{"pubmed":["34473645"],"doi":["10.1172/JCI151800","10.1172/jci151800"]}}